United States Biotechnology & Medical Research

Galectin Therapeutics Inc (GALT)

Track

Over the past 90 days, Galectin Therapeutics Inc. insiders have executed 12 transactions, all involving sales totaling approximately $1.04 million. Key executives, including the Chief Medical Officer and a Director, conducted these planned and proposed sales. This activity follows a 34.7% stock price increase over the last quarter, despite the stock trading near its 52-week low.
Ticker: GALT Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Galectin Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 14 Jul 2026
Value US$3,808,770.34 | Price 95.02 | Shares 47,887 (-33.9%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-16 2026-07-14 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
47,887 -33.9%
95.02
US$3,808,770 		47,887 -33.9% 95.02 US$3,808,770
2026-06-30 2026-06-29 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
19,874 -18.7%
418.07
US$4,014,068 		19,874 -18.7% 418.07 US$4,014,068
2026-06-30 2026-06-29 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
52,256 +23.5%
126.79
US$3,365,202 		52,256 +23.5% 126.79 US$3,365,202
2026-06-29 2026-06-29 PrS Proposed sale
2.9
Harold Shlevin

Director

Non-Executive Director
22,268
5.04
US$112,212 		22,268 5.04 US$112,212
2026-06-30 2026-06-26 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
7,732 -54.3%
5.00
US$38,660 		7,732 -54.3% 5.00 US$38,660
2026-06-30 2026-06-26 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
2,533 -100.0%
5.00
US$12,665 		2,533 -100.0% 5.00 US$12,665
2026-06-30 2026-06-26 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
2,037 -100.0%
5.00
US$10,185 		2,037 -100.0% 5.00 US$10,185
2026-06-26 2026-06-26 PrS Proposed sale
Jamil Khurram

Officer

Officer
68,287
5.00
US$341,435 		68,287 5.00 US$341,435
2026-06-26 2026-06-26 PrS Proposed sale
2.9
HAROLD SHLEVIN

DIRECTOR

Non-Executive Director
7,732
5.00
US$38,680 		7,732 5.00 US$38,680
2026-06-25 2026-06-23 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
7,557 -100.0%
3.14
US$23,729 		7,557 -100.0% 3.14 US$23,729
2026-06-23 2026-06-23 PrS Proposed sale
Jamil Khurram

Officer

Officer
8,125
3.14
US$25,500 		8,125 3.14 US$25,500
2026-05-28 2026-05-26 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
568 -100.0%
3.10
US$1,761 		568 -100.0% 3.10 US$1,761
2026-02-09 2026-02-06 B Purchase
4.1
ELDRED KARY
Non-Executive Director
300 +0.5%
2.70
US$810 		300 +0.5% 2.70 US$810
2026-01-06 2026-01-06 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
21,446 -100.0%
3.65
US$78,205 		21,446 -100.0% 3.65 US$78,205
2026-01-06 2026-01-06 PlS Planned sale
2.3
CALLICUTT JACK W

Chief Financial Officer

Officer
20,354 -72.8%
3.67
US$74,695 		20,354 -72.8% 3.67 US$74,695
2026-01-06 2026-01-06 PlS Planned sale
2.3
LEWIS JOEL

President and CEO

Executive Director
37,698 -4.3%
3.58
US$134,853 		37,698 -4.3% 3.58 US$134,853
2026-01-06 2026-01-05 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
25,499 -54.3%
3.90
US$99,408 		25,499 -54.3% 3.90 US$99,408
2026-01-06 2026-01-05 PlS Planned sale
2.3
CALLICUTT JACK W

Chief Financial Officer

Officer
25,732 -47.9%
3.90
US$100,298 		25,732 -47.9% 3.90 US$100,298
2026-01-06 2026-01-05 PlS Planned sale
2.3
LEWIS JOEL

President and CEO

Executive Director
27,731 -3.1%
3.91
US$108,342 		27,731 -3.1% 3.91 US$108,342
2026-01-06 2026-01-02 PrS Proposed sale
2.9
Shlevin Harold H.

Director

Non-Executive Director
441,500
4.16
US$1,836,640 		441,500 4.16 US$1,836,640
2026-01-06 2026-01-02 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
13,055 -21.8%
4.20
US$54,789 		13,055 -21.8% 4.20 US$54,789
2026-01-06 2026-01-02 PlS Planned sale
2.3
CALLICUTT JACK W

Chief Financial Officer

Officer
13,914 -20.6%
4.20
US$58,394 		13,914 -20.6% 4.20 US$58,394
2026-01-06 2026-01-02 PlS Planned sale
2.3
LEWIS JOEL

President and CEO

Executive Director
18,571 -2.0%
4.20
US$77,939 		18,571 -2.0% 4.20 US$77,939
2026-01-05 2026-01-02 PrS Proposed sale
2.3
CALLICUTT JACK W

Officer

Officer
60,000
4.20
US$252,000 		60,000 4.20 US$252,000
2026-01-02 2026-01-02 PrS Proposed sale
2.3
LEWIS JOEL

Officer

Officer
84,000
4.20
US$352,800 		84,000 4.20 US$352,800
2026-01-02 2026-01-02 PrS Proposed sale
Jamil Khurram

Officer

Officer
60,000
4.20
US$252,000 		60,000 4.20 US$252,000
2026-01-02 2026-01-02 PrS Proposed sale
2.3
CALLICUTT JACK W

Officer

Officer
141,206
4.20
US$593,065 		141,206 4.20 US$593,065
2026-01-05 2025-12-31 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
8,125 -100.0%
4.07
US$33,089 		8,125 -100.0% 4.07 US$33,089
2025-12-23 2025-12-23 B Purchase
4.1
ELDRED KARY
Non-Executive Director
700 +1.1%
3.73
US$2,611 		700 +1.1% 3.73 US$2,611
2025-12-23 2025-12-23 B Purchase
3.2
FREEMAN KEVIN D
Non-Executive Director
5,500 +11.1%
3.55
US$19,514 		5,500 +11.1% 3.55 US$19,514
2025-12-23 2025-12-23 B Purchase
4.1
ELDRED KARY
Non-Executive Director
700 +1.1%
3.73
US$2,611 		700 +1.1% 3.73 US$2,611
2025-12-19 2025-12-17 PlS Planned sale
2.3
LEWIS JOEL

President and CEO

Executive Director
7,829 -0.9%
7.06
US$55,241 		7,829 -0.9% 7.06 US$55,241
2025-12-19 2025-12-17 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
4,706 -42.0%
7.04
US$33,121 		4,706 -42.0% 7.04 US$33,121
2025-12-19 2025-12-17 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
19,793 -63.9%
7.04
US$139,303 		19,793 -63.9% 7.04 US$139,303
2025-12-19 2025-12-17 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
8,500 -100.0%
7.04
US$59,840 		8,500 -100.0% 7.04 US$59,840
2025-12-19 2025-12-17 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
6,463 -100.0%
7.04
US$45,500 		6,463 -100.0% 7.04 US$45,500
2025-12-19 2025-12-17 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
4,479 -100.0%
7.04
US$31,532 		4,479 -100.0% 7.04 US$31,532
2025-12-17 2025-12-17 PrS Proposed sale
Jamil Khurram

Officer

Officer
21,479
7.04
US$151,212 		21,479 7.04 US$151,212
2025-12-17 2025-12-17 PrS Proposed sale
2.3
LEWIS JOEL

Officer

Officer
40,000
7.06
US$282,244 		40,000 7.06 US$282,244
2025-12-17 2025-12-17 PrS Proposed sale
2.9
HAROLD SHLEVIN

DIRECTOR

Non-Executive Director
24,706
6.97
US$172,223 		24,706 6.97 US$172,223
2025-12-18 2025-12-16 S Sale
4.3
10X Fund, L.P.
Large shareholder
30,681 -0.5%
6.66
US$204,335 		30,681 -0.5% 6.66 US$204,335
2025-12-16 2025-12-15 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
8,417 -42.9%
6.30
US$53,027 		8,417 -42.9% 6.30 US$53,027
2025-12-15 2025-12-15 PrS Proposed sale
2.9
HAROLD SHLEVIN

DIRECTOR

Non-Executive Director
8,417
6.24
US$52,542 		8,417 6.24 US$52,542
2025-12-16 2025-12-12 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
19,793 -63.9%
6.27
US$124,181 		19,793 -63.9% 6.27 US$124,181
2025-12-15 2025-12-12 PrS Proposed sale
2.9
HAROLD SHLEVIN

DIRECTOR

Non-Executive Director
19,793
6.21
US$122,993 		19,793 6.21 US$122,993
2025-12-12 2025-12-12 PrS Proposed sale
2.9
HAROLD SHLEVIN

DIRECTOR

Non-Executive Director
19,793
6.21
US$122,993 		19,793 6.21 US$122,993
2025-12-10 2025-12-09 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
16,790 -60.0%
6.27
US$105,206 		16,790 -60.0% 6.27 US$105,206
2025-12-09 2025-12-09 PrS Proposed sale
2.9
HAROLD SHLEVIN

DIRECTOR

Non-Executive Director
16,790
6.21
US$104,198 		16,790 6.21 US$104,198
2025-12-10 2025-12-08 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
20,000 -64.1%
6.00
US$120,040 		20,000 -64.1% 6.00 US$120,040
2025-12-10 2025-12-08 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
35,000 -75.7%
6.02
US$210,665 		35,000 -75.7% 6.02 US$210,665
2025-12-10 2025-12-08 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
25,000 -69.0%
5.95
US$148,650 		25,000 -69.0% 5.95 US$148,650
2025-12-10 2025-12-08 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
20,000 -64.1%
5.96
US$119,240 		20,000 -64.1% 5.96 US$119,240
2025-12-10 2025-12-08 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
20,000 -64.1%
5.96
US$119,240 		20,000 -64.1% 5.96 US$119,240
2025-12-10 2025-12-08 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
35,000 -75.7%
5.95
US$208,250 		35,000 -75.7% 5.95 US$208,250
2025-12-10 2025-12-08 PlS Planned sale
2.9
Shlevin Harold H.
Non-Executive Director
4,000 -26.3%
6.01
US$24,020 		4,000 -26.3% 6.01 US$24,020
2025-12-08 2025-12-08 PrS Proposed sale
2.9
HAROLD SHLEVIN

DIRECTOR

Non-Executive Director
159,000
6.02
US$957,180 		159,000 6.02 US$957,180
2025-12-04 2025-12-03 S Sale
4.3
10X Fund, L.P.
Large shareholder
120,000 -2.1%
5.73
US$687,600 		120,000 -2.1% 5.73 US$687,600
2025-12-04 2025-12-02 S Sale
4.3
10X Fund, L.P.
Large shareholder
30,000 -0.5%
5.47
US$164,100 		30,000 -0.5% 5.47 US$164,100
2025-11-19 2025-11-18 PlS Planned sale
2.3
CALLICUTT JACK W

Chief Financial Officer

Officer
18,210 -70.5%
6.22
US$113,321 		18,210 -70.5% 6.22 US$113,321
2025-11-19 2025-11-18 PlS Planned sale
2.3
CALLICUTT JACK W

Chief Financial Officer

Officer
28,100 -78.7%
6.22
US$174,866 		28,100 -78.7% 6.22 US$174,866
2025-11-19 2025-11-18 PlS Planned sale
2.3
LEWIS JOEL

President and CEO

Executive Director
6,783 -0.8%
6.15
US$41,723 		6,783 -0.8% 6.15 US$41,723
2025-11-19 2025-11-17 PlS Planned sale
2.3
CALLICUTT JACK W

Chief Financial Officer

Officer
2,323 -23.4%
6.03
US$14,012 		2,323 -23.4% 6.03 US$14,012
2025-11-19 2025-11-17 PlS Planned sale
2.3
CALLICUTT JACK W

Chief Financial Officer

Officer
19,701 -72.1%
6.03
US$118,831 		19,701 -72.1% 6.03 US$118,831
2025-11-19 2025-11-17 PlS Planned sale
2.3
CALLICUTT JACK W

Chief Financial Officer

Officer
9,586 -55.7%
6.03
US$57,820 		9,586 -55.7% 6.03 US$57,820
2025-11-19 2025-11-17 PlS Planned sale
2.3
LEWIS JOEL

President and CEO

Executive Director
15,680 -1.8%
6.04
US$94,643 		15,680 -1.8% 6.04 US$94,643
2025-11-14 2025-11-13 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
16,250 -78.4%
5.47
US$88,888 		16,250 -78.4% 5.47 US$88,888
2025-11-14 2025-11-13 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
41,500 -90.3%
5.47
US$227,005 		41,500 -90.3% 5.47 US$227,005
2025-11-14 2025-11-13 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
41,500 -90.3%
5.47
US$227,005 		41,500 -90.3% 5.47 US$227,005
2025-11-14 2025-11-13 PlS Planned sale
Jamil Khurram

Chief Medical Officer

Officer
21,867 -83.0%
5.47
US$119,612 		21,867 -83.0% 5.47 US$119,612
2025-11-13 2025-11-13 PrS Proposed sale
Jamil Khurram

Officer

Officer
121,117
5.45
US$660,088 		121,117 5.45 US$660,088
2025-11-12 2025-11-11 S Sale
4.3
10X Fund, L.P.
Large shareholder
40,000 -0.7%
5.25
US$210,000 		40,000 -0.7% 5.25 US$210,000
2025-11-12 2025-11-10 PlS Planned sale
2.3
LEWIS JOEL

President and CEO

Executive Director
1,867 -0.2%
6.03
US$11,252 		1,867 -0.2% 6.03 US$11,252
2025-11-12 2025-11-10 PlS Planned sale
2.3
CALLICUTT JACK W

Chief Financial Officer

Officer
1,736 -18.6%
6.03
US$10,468 		1,736 -18.6% 6.03 US$10,468
2025-11-12 2025-11-10 PlS Planned sale
2.3
CALLICUTT JACK W

Chief Financial Officer

Officer
1,675 -18.0%
6.03
US$10,095 		1,675 -18.0% 6.03 US$10,095
2025-11-12 2025-11-10 PlS Planned sale
2.3
CALLICUTT JACK W

Chief Financial Officer

Officer
1,880 -19.8%
6.02
US$11,321 		1,880 -19.8% 6.02 US$11,321
Explore more

More insider trading research around Galectin Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America